卵巢癌患者治疗前血清中的肿瘤发生发展相关蛋白浓度。

Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment.

作者信息

Pledger D R, Belfield A, Kennedy J H, Kaye S B

机构信息

Department of Pathological Biochemistry, Royal Infirmary, Glasgow, U.K.

出版信息

Eur J Cancer Clin Oncol. 1988 Feb;24(2):219-22. doi: 10.1016/0277-5379(88)90256-8.

DOI:10.1016/0277-5379(88)90256-8

PMID:3356210

Abstract

Eight onco-developmental proteins have been measured in the serum of women prior to their operation and treatment for ovarian cancer. Alpha-foetoprotein, CEA, hCG and PAPP-A were not often elevated whereas CPAP, SP1, CanAg 50 and CA 125 were. Many of our findings differed from those of previous workers, possibly due to differences in clinical material and analytical technique. We conclude that large profiles of tumour markers are no longer of use in the investigation of ovarian cancer. At the present time we think that CA 125 could prove the most useful marker in the investigation of ovarian cancer.

摘要

在患有卵巢癌的女性进行手术和治疗之前，已对其血清中的八种肿瘤发生发展相关蛋白进行了检测。甲胎蛋白、癌胚抗原、人绒毛膜促性腺激素和妊娠相关血浆蛋白-A通常未升高，而癌胚蛋白、鳞状上皮细胞癌抗原、癌抗原50和癌抗原125则升高。我们的许多研究结果与之前研究者的不同，这可能是由于临床材料和分析技术的差异所致。我们得出结论，大量的肿瘤标志物组合在卵巢癌的研究中已不再有用。目前我们认为，癌抗原125可能是卵巢癌研究中最有用的标志物。